Biobot Surgical Pte Ltd

Biobot Surgical is a Singapore-based manufacturer of robotic-assisted surgical systems for transperineal prostate procedures and soft tissue ablation. The company's flagship product, the Mona Lisa platform, delivers submillimeter robotic accuracy (±1.0 mm) for precision needle positioning in prostate biopsy and treatment applications. The Mona Lisa [DX] system, launched in 2017, enables MRI-ultrasound image fusion for targeted prostate biopsies with higher detection rates than traditional transrectal approaches and minimal infection risk. The newer Mona Lisa 2.0 [TX] expands indications to include percutaneous soft tissue ablation therapy. The company reports over 50 systems installed globally and more than 23,000 completed procedures as of January 2024. Regulatory credentials include FDA clearance for both DX and TX models, CE certification (TX model), TGA approval (Australia), NMPA clearance (China), and HSA approval (Singapore). Biobot operates a development pipeline including the Mona Lisa ACCuESS platform to expand sites of care and clinical indications. The company maintains a USA office in Saint Paul, Minnesota, headquarters in Singapore, and an Asia-Pacific regional office in Shanghai. Target market includes hospital urology departments and ambulatory surgery centers performing prostate cancer diagnostics and therapeutic interventions.